

SELL TP: Rs 551 | ¥ 26%

JK LAKSHMI CEMENT

Cement

14 February 2023

Cost overruns remain a concern

- Q3 volumes surged 16% YoY on a weak base with realisations up 8%, aiding healthy topline growth
- Despite strong realisation gains, EBITDA margin contracted 160bps
 YoY as costs spiked
- Valuations are running ahead of fundamentals; maintain SELL with an unchanged TP of Rs 551

Milind Raginwar | Yash Thakur research@bobcaps.in

Volumes healthy on a weak base: JKLC's Q3FY23 revenue increased 25% YoY (+14% QoQ) to Rs 14.9bn, supported by 16% higher volumes (+17% QoQ) to 2.7mt (including clinker sales) and an 8% rise in realisations (-2% QoQ) to Rs 5,325/t. Volume growth though optically strong is on a weak base YoY and also reflects favourable seasonality QoQ.

Costs elevated: Operating cost increased by 10% YoY (-2% QoQ) to Rs 4,940/t, largely due to a 19% rise in energy and raw material cost to Rs 2,256/t. The energy cost curve, however, is flattening with a sequential uptick of only 1%. External purchases grew 15% YoY to Rs 594/t. Logistics cost/t was up 2% YoY (+1% QoQ) to Rs 1,094/t as JKLC lacks rail transport at its eastern facility (Durg). Other expenditure climbed 22% YoY (+24% QoQ) to Rs 1.8bn, which raised overall costs and put pressure on margins.

Margins soft despite healthy realisation gains: Q3 EBITDA grew 9% YoY (+15% QoQ) to Rs 1.6bn, but higher costs caused the EBITDA margin to contract from 12.3% in the year-ago quarter to 10.7% (flattish QoQ). EBITDA/t fell 6% YoY to Rs 593/t (-1% QoQ). PAT grew 24% YoY (+25% QoQ) to Rs 736mn.

Capacity expansion delayed: Capacity expansion at Udaipur (Rajasthan) that was scheduled for commissioning in Q4FY24 is guided to be delayed to Q1FY25. Management indicated that JKLC will add another 12mt of capacity and has plans to reach 30mt by 2030.

Maintain SELL: In our view, current valuations at 10.5x FY25E EV/EBITDA have outrun earnings growth potential considering JKLC's financial and operational structure. Past experience also suggests that the company's capex execution has been less than ideal, leading to delays (in-house and at subsidiary UCWL as well). We maintain our SELL rating and continue to value the stock at 8x FY25E EV/EBITDA for an unchanged TP of Rs 551. Our TP implies a replacement cost of Rs 6.6bn/mt – a 6% discount to the industry benchmark (for details, see our initiation report).

Key changes

_	•		
	Target	Rating	
	< ▶	< ▶	

Ticker/Price	JKLC IN/Rs 747
Market cap	US\$ 1.1bn
Free float	54%
3M ADV	US\$ 5.6mn
52wk high/low	Rs 897/Rs 366
Promoter/FPI/DII	46%/14%/26%

Source: NSE | Price as of 14 Feb 2023

Key financials

Y/E 31 Mar	FY22A	FY23E	FY24E
Total revenue (Rs mn)	50,408	62,533	67,356
EBITDA (Rs mn)	8,013	7,027	7,855
Adj. net profit (Rs mn)	4,496	3,260	3,874
Adj. EPS (Rs)	38.2	27.7	32.9
Consensus EPS (Rs)	38.2	34.4	44.2
Adj. ROAE (%)	19.6	12.7	13.6
Adj. P/E (x)	19.5	26.9	22.7
EV/EBITDA (x)	10.9	13.2	11.6
Adj. EPS growth (%)	13.9	(27.5)	18.8

Source: Company, Bloomberg, BOBCAPS Research

Stock performance



Source: NSE





Earnings call highlights

- Cement prices improved marginally in Q3FY23. Management expects a focus on volume growth and operating efficiencies to aid margin expansion beyond realisation upsides.
- JKLC is targeting cement volume growth of 12% for FY23 and 12-15% for FY24.
 Volumes are expected to clock in at ~50k/month at the Amethi grinding unit in Uttar Pradesh.
- Capacity utilisation increased to 85% in Q3 from 77% in the prior quarter.
- Fuel cost in Q3 was Rs 2.57/kcal (against Rs 2.30/kcal in Q2), and management expects it to remain flat in Q4. Other expenditure is guided to remain at Q3 levels, as is fuel cost inventory, with the latter likely to start trending down from Q1FY24.
- JKLC is targeting EBITDA/t of Rs 1,000 in the next 18-24 months from Rs 650 currently, of which it expects Rs 200+ will come from topline levers, Rs 50 from manufacturing efficiencies and Rs 50 from supply chain improvement.
- Operating margin for AAC (autoclaved aerated concrete) blocks stood at 12%. Other products earned a 7% margin (5% in Q2FY23 and 3% in Q3FY22), which is guided to be in the region of 7-8% in FY24. The Aligarh plant was acquired recently for the AAC block and production has begun. A putty plant will be set up in the 6-9 months at Alwar facility in Rajasthan.
- Trade share was at 54%, blended share at 66% and premium share at 11% of Q3 volumes. Lead distance stood at 396km against 401km in Q2. With respect to achieving its earlier target of +60% trade share and 70-75% blended share, management indicated that its priority is optimisation of the geographical mix.
- To further optimise energy costs, JKLC is implementing a project that will enable it to enhance the thermal substitution rate from 4% to 12% at its Sirohi (Rajasthan) unit. The company has also tied up with a private player for the supply of 40MW of solar power for its Durg (Chhattisgarh) plant. Following this, the share of renewable energy would rise to 80% at Durg and ~50% for the company as a whole. Both these projects are expected to be commissioned by Q4FY24.
- Management indicated that JKLC will add another 12mt of capacity and has plans to reach 30mt by 2030.
- The company has limestone leases in three locations (Durg, Nagaur and Kutch).
 Nagaur (Rajasthan) is the top priority (for capacity addition) followed by Durg and then Kutch (Gujarat). Sirohi is due for lease auctions in 2030.
- Capex (standalone) incurred in Q3FY23 was at Rs 2.5bn. A sum of Rs 2bn is to be incurred in Q4FY23 and Rs 7.5bn in FY24.



Fig 1 – Key metrics

(Rs)	Q3FY23	Q3FY22	YoY (%)	Q2FY23	QoQ (%)
Volumes (mt)	2.7	2.3	15.5	2.3	16.7
Cement realisations (Rs/mt)	5,325	4,945	7.7	5,426	(1.9)
Operating costs (Rs/mt)	4,940	4,496	9.9	5,050	(2.2)
EBITDA (Rs/mt)	593	629	(5.6)	601	(1.3)

Source: Company, BOBCAPS Research


Fig 2 - Quarterly performance

(Rs mn)	Q3FY23	Q3FY22	YoY (%)	Q2FY23	QoQ (%)
Net Sales	14,885	11,934	24.7	13,027	14.3
Expenditure					
Change in stock	(736)	(484)	52.2	(342)	115.4
Raw material	2,461	1,984	24.1	2,175	13.2
Purchased products	1,598	1,206	32.6	1,698	(5.9)
Power & fuel	4,345	2,932	48.2	3,332	30.4
Freight	2,942	2,486	18.3	2,494	18.0
Employee costs	877	868	1.1	833	5.3
Other expenditure	1,802	1,479	21.9	1,451	24.2
Total Operating Expenses	13,289	10,470	26.9	11,640	14.2
EBITDA	1,596	1,464	9.0	1,386	15.1
EBITDA margin (%)	10.7	12.3	(155bps)	10.6	8bps
Other Income	156	164	(5.0)	214	(27.1)
Interest	247	251	(1.4)	226	9.3
Depreciation	480	468	2.6	481	(0.1)
PBT	1,025	910	12.6	894	14.7
Non-recurring items	0	0	0.0	0	0.0
PBT (after non-recurring items)	1,025	910	12.6	894	14.7
Tax	289	318	(9.0)	304	(5.0)
Tax Rate (%)	28	35	(671bps)	34	(584bps)
Reported PAT	736	592	24.2	590	24.8
Adjusted PAT	736	592	24.2	590	25
NPM (%)	4.9	5.0	(2bps)	4.5	42bps
Adjusted EPS (Rs)	6.3	5.0	24.2	5.0	25

Source: Company, BOBCAPS Research



Fig 3 – Volumes moved up on a weak base, also aided by new contract manufacturing



Source: Company, BOBCAPS Research

Fig 5 - EBITDA/t softened




Source: Company, BOBCAPS Research

Fig 7 – Logistics cost to stay elevated till Durg railway siding becomes operational




Source: Company, BOBCAPS Research

Fig 4 - Realisation gains offset by cost spiral




Source: Company, BOBCAPS Research

Fig 6 – Other expenses and energy cost pushed up overall expenditure



Source: Company, BOBCAPS Research

Fig 8 - Energy cost climbed higher



Source: Company, BOBCAPS Research



Valuation methodology

In our view, current valuations at 10.5x FY25E EV/EBITDA have outrun JKLC's earnings growth potential considering its elevated cost structure. Past experience also suggests that the company's capex execution has been less than smooth, leading to delays in commissioning new capacities, thereby clouding growth prospects (expansion at subsidiary Udaipur Cement Works has been pushed back, in stark contrast to peers who have been fast-tracking capacity addition).

Factoring in the same, we continue to value the stock at 8x FY25E EV/EBITDA for an unchanged TP of Rs 551 and maintain our SELL rating. Our TP implies a replacement cost of Rs 6.6bn/mt – 6% discount to the industry benchmark. Apart from the current urgency for capex due to the limited capacity headroom available to the company, we would also await a more consistent operating performance backed by judicious capital allocation before revisiting our estimates.

Fig 9 - Key assumptions

Parameter	FY22	FY23E	FY24E	FY25E
Volumes (mt)	10.3	11.1	12.2	13.4
Realisations (Rs/mt)	4,494	5,483	5,510	5,538
Operating costs (Rs/mt)	4,132	4,996	4,869	4,774
EBITDA (Rs/mt)	781	633	643	711

Source: Company, BOBCAPS Research

Fig 10 - Valuation summary

Business (Rs mn)	FY25E
Target EV/EBITDA (x)	8
EBITDA	9,552
Target EV	76,419
Total EV	76,419
Net debt	11,601
Target market capitalisation	64,818
Target price (Rs/sh)	551
Weighted average shares (mn)	118
o populpo p	

Source: BOBCAPS Research

Fig 11 - Peer comparison

Ticker Rating		. Dating TP		EV/EBITDA (x)		EV/tonne (US\$)		ROE (%)			ROCE (%)			
ricker	Rating	(Rs)	FY23E	FY24E	FY25E	FY23E	FY24E	FY25E	FY23E	FY24E	FY25E	FY23E	FY24E	FY25E
JKLC IN	SELL	551	13.2	11.6	10.4	93	92	100	12.7	13.6	14.6	16.8	17.7	17.4
JKCE IN	BUY	3,371	16.5	13.6	10.4	205	201	197	17.0	17.8	19.2	16.2	17.0	19.1
TRCL IN	SELL	534	21.6	16.9	13.1	123	123	124	3.2	6.0	8.5	4.5	6.6	8.7

Source: BOBCAPS Research



Key risks

Key upside risks to our estimates are:

- higher demand driving better pricing in JKLC's key areas of operation,
- operating performance improving ahead of our estimates, and
- timely capex execution.

Sector recommendation snapshot

Company	Ticker	Market Cap (US\$ bn)	Price (Rs)	Target (Rs)	Rating
ACC	ACC IN	4.2	1,830	2,090	HOLD
Ambuja Cement	ACEM IN	8.1	337	387	HOLD
Dalmia Bharat	DALBHARA IN	4.5	1,903	1,835	HOLD
JK Cement	JKCE IN	2.6	2,742	3,371	BUY
JK Lakshmi Cement	JKLC IN	1.1	747	551	SELL
Orient Cement	ORCMNT IN	0.3	121	140	HOLD
Shree Cement	SRCM IN	10.7	24,635	24,656	HOLD
Star Cement	STRCEM IN	0.6	110	138	BUY
The Ramco Cements	TRCL IN	2.1	723	534	SELL
Ultratech Cement	UTCEM IN	24.9	7,139	8,310	BUY

Source: BOBCAPS Research, NSE | Price as of 14 Feb 2023



Financials

Y/E 31 Mar (Rs mn)	FY21A	FY22A	FY23E	FY24E	FY25E
Total revenue	43,847	50,408	62,533	67,356	73,729
EBITDA	7,898	8,013	7,027	7,855	9,552
Depreciation	(1,942)	(1,905)	(1,941)	(1,992)	(2,303)
EBIT	6,700	6,780	5,823	6,699	8,107
Net interest inc./(exp.)	(1,425)	(963)	(883)	(874)	(1,027
Other inc./(exp.)	745	673	737	837	858
Exceptional items	(309)	(234)	0	0	(
EBT	4,966	5,583	4,940	5,826	7,080
Income taxes	(1,328)	(1,321)	(1,680)	(1,952)	(2,372)
Extraordinary items	0	0	0	0	(
Min. int./Inc. from assoc.	0	0	0	0	(
Reported net profit	3,638	4,262	3,260	3,874	4,708
Adjustments	309	234	0	0	(
Adjusted net profit	3,947	4,496	3,260	3,874	4,708
Balance Sheet					
Y/E 31 Mar (Rs mn)	FY21A	FY22A	FY23E	FY24E	FY25E
Accounts payables	10,764	7,658	13,838	14,835	15,649
Other current liabilities	6,315	7,046	7,237	7,458	7,680
Provisions	201	267	760	789	82
Debt funds	7,904	7,953	8,865	9,525	18,814
Other liabilities	641	943	150	170	198
Equity capital	588	588	588	588	588
Reserves & surplus	20,209	23,419	26,221	29,545	33,702
Shareholders' fund	20,797	24,523	26,810	30,133	34,29
Total liab. and equities	46,622	48,390	57,660	62,909	77,452
Cash and cash eq.	7,270	8,869	4,047	6,291	7,213
Accounts receivables	537	345	1,628	1,753	2,12
Inventories	3,155	4,912	6,767	7,289	8,383
Other current assets	2,932	2,003	5,952	6,547	7,202
Investments	3,833	3,899	3,948	3,998	4,049
Net fixed assets	26,371	27,134	27,210	27,416	40,359
CWIP	2,451	1,127	8,000	9,500	8,000
Intangible assets	72	103	108	116	127
Deferred tax assets, net	0	0	0	0	(
Other assets	0	0	0	0	(
Total assets	46,621	48,390	57,660	62,909	77,452
Cash Flows					
Y/E 31 Mar (Rs mn)	FY21A	FY22A	FY23E	FY24E	FY25E
Cash flow from operations	7,992	3,537	4,185	5,889	5,991
Capital expenditures	(1,180)	(1,386)	(8,896)	(3,706)	(13,757
Change in investments	352	(1,867)	2,731	(2,350)	(1,051
Other investing cash flows	0	0	0	0	(
Cash flow from investing	(828)	(3,253)	(6,164)	(6,056)	(14,808
Equities issued/Others	0	516	(516)	0	(
Debt raised/repaid	(3,926)	49	912	660	9,289
Interest expenses	0	0	0	0	(
Dividends paid	(441)	(441)	(471)	(471)	(471
Other financing cash flows	473	(609)	14	(79)	(79
Cash flow from financing	(3,894)	(486)	(61)	110	8,739
Chg in cash & cash eq.	3,270	(202)	(2,040)	(56)	(78
Closing cash & cash eq.	7,270	8,869	4,048	6,291	7,213

Per Share					
Y/E 31 Mar (Rs)	FY21A	FY22A	FY23E	FY24E	FY25E
Reported EPS	30.9	36.2	27.7	32.9	40.0
Adjusted EPS	33.5	38.2	27.7	32.9	40.0
Dividend per share	3.8	3.8	4.0	4.0	4.0
Book value per share	176.7	208.4	227.8	256.1	291.4
Valuations Ratios					
Y/E 31 Mar (x)	FY21A	FY22A	FY23E	FY24E	FY25E
EV/Sales	2.0	1.7	1.5	1.4	1.3
EV/EBITDA	11.2	10.9	13.2	11.6	10.4
Adjusted P/E	22.3	19.5	26.9	22.7	18.7
P/BV	4.2	3.6	3.3	2.9	2.6
DuPont Analysis					
Y/E 31 Mar (%)	FY21A	FY22A	FY23E	FY24E	FY25E
Tax burden (Net profit/PBT)	73.3	76.3	66.0	66.5	66.5
Interest burden (PBT/EBIT)	78.7	85.8	84.8	87.0	87.3
EBIT margin (EBIT/Revenue)	15.3	13.5	9.3	9.9	11.0
Asset turnover (Rev./Avg TA)	95.2	106.1	117.9	111.7	105.
Leverage (Avg TA/Avg Equity)	2.4	2.1	2.1	2.1	2.2
Adjusted ROAE	20.4	19.6	12.7	13.6	14.6
Ratio Analysis					
Y/E 31 Mar	FY21A	FY22A	FY23E	FY24E	FY25E
YoY growth (%)					
Revenue	8.4	15.0	24.1	7.7	9.5
EBITDA	17.5	1.5	(12.3)	11.8	21.6
Adjusted EPS	48.7	13.9	(27.5)	18.8	21.5
Profitability & Return ratios (%)					
EBITDA margin	18.0	15.9	11.2	11.7	13.0
EBIT margin	15.3	13.5	9.3	9.9	11.0
Adjusted profit margin	9.0	8.9	5.2	5.8	6.4
Adjusted ROAE	20.4	19.6	12.7	13.6	14.6
ROCE	22.9	21.6	16.8	17.7	17.4
Working capital days (days)					
Receivables	4	2	10	10	11
Inventory	26	36	40	40	42
Payables	109	66	91	91	89
Ratios (x)					
Gross asset turnover	1.2	1.3	1.5	1.5	1.2
Ott'-	0.0		0.0	0.0	

Adjusted debt/equity 0.4 0.3

Source: Company, BOBCAPS Research | Note: TA = Total Assets

0.8

4.7

1.1

7.0

0.8

6.6

0.3

0.9

7.7

0.3

1.0

7.9

0.5

Current ratio

Net interest coverage ratio



NOT FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA ("US") OR IN OR INTO ANY OTHER JURISDICTION IF SUCH AN ACTION IS PROHIBITED BY APPLICABLE LAW.

Disclaimer

Recommendation scale: Recommendations and Absolute returns (%) over 12 months

BUY - Expected return >+15%

HOLD - Expected return from -6% to +15%

SELL - Expected return <-6%

Note: Recommendation structure changed with effect from 21 June 2021

Our recommendation scale does not factor in short-term stock price volatility related to market fluctuations. Thus, our recommendations may not always be strictly in line with the recommendation scale as shown above.

Ratings and Target Price (3-year history): JK LAKSHMI CEMENT (JKLC IN)



B - Buy, H - Hold, S - Sell, A - Add, R - Reduce

Analyst certification

The research analyst(s) authoring this report hereby certifies that (1) all of the views expressed in this research report accurately reflect his/her personal views about the subject company or companies and its or their securities, and (2) no part of his/her compensation was, is, or will be, directly or indirectly, related to the specific recommendation(s) or view(s) in this report. Analysts are not registered as research analysts by FINRA and are not associated persons of BOB Capital Markets Limited (BOBCAPS).

General disclaimers

BOBCAPS is engaged in the business of Stock Broking and Investment Banking. BOBCAPS is a member of the National Stock Exchange of India Limited and BSE Limited and is also a SEBI-registered Category I Merchant Banker. BOBCAPS is a wholly owned subsidiary of Bank of Baroda which has its various subsidiaries engaged in the businesses of stock broking, lending, asset management, life insurance, health insurance and wealth management, among others.

BOBCAPS's activities have neither been suspended nor has it defaulted with any stock exchange authority with whom it has been registered in the last five years. BOBCAPS has not been debarred from doing business by any stock exchange or SEBI or any other authority. No disciplinary action has been taken by any regulatory authority against BOBCAPS affecting its equity research analysis activities.

BOBCAPS has obtained registration as a Research Entity under SEBI (Research Analysts) Regulations, 2014, having registration No.: INH000000040 valid till 03 February 2025. BOBCAPS is also a SEBI-registered intermediary for the broking business having SEBI Single Registration Certificate No.: INZ000159332 dated 20 November 2017. BOBCAPS CIN Number: U65999MH1996GOI098009.

BOBCAPS prohibits its analysts, persons reporting to analysts, and members of their households from maintaining a financial interest in the securities or derivatives of any companies that the analysts cover. Additionally, BOBCAPS prohibits its analysts and persons reporting to analysts from serving as an officer, director, or advisory board member of any companies that the analysts cover.

Our salespeople, traders, and other professionals may provide oral or written market commentary or trading strategies to our clients that reflect opinions contrary to the opinions expressed herein, and our proprietary trading and investing businesses may make investment decisions that are inconsistent with the recommendations expressed herein. In reviewing these materials, you should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest. Additionally, other important information regarding our relationships with the company or companies that are the subject of this material is provided herein.

This material should not be construed as an offer to sell or the solicitation of an offer to buy any security in any jurisdiction. We are not soliciting any action based on this material. It is for the general information of BOBCAPS's clients. It does not constitute a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual clients. Before acting on any advice or recommendation in this material, clients should consider whether it is suitable for their particular circumstances and, if necessary, seek professional advice. BOBCAPS research reports follow rules laid down by Securities and Exchange Board of India and individuals employed as research analysts are separate from other employees who are performing sales trading, dealing, corporate finance advisory or any other activity that may affect the independence of its research reports.

The price and value of the investments referred to in this material and the income from them may go down as well as up, and investors may realize losses on any investments. Past performance is not a guide for future performance, future returns are not guaranteed and a loss of original capital may occur. BOBCAPS does not provide tax advice to its clients, and all investors are strongly advised to consult with their tax advisers regarding any potential investment in certain transactions — including those involving futures, options, and other derivatives as well as non-investment-grade securities — that give rise to substantial risk and are not suitable for all investors. The material is based on information that we consider reliable, but we do not represent that it is accurate or complete, and it should not be relied on as such. Opinions expressed are our current opinions as of the date appearing on this material only. We endeavour to update on a reasonable basis the information discussed in this material, but regulatory, compliance, or other reasons may prevent us from doing so.

JK LAKSHMI CEMENT



We and our affiliates, officers, directors, and employees, including persons involved in the preparation or issuance of this material, may from time to time have "long" or "short" positions in, act as principal in, and buy or sell the securities or derivatives thereof of companies mentioned herein and may from time to time add to or dispose of any such securities (or investment). We and our affiliates may assume an underwriting commitment in the securities of companies discussed in this document (or in related investments), may sell them to or buy them from customers on a principal basis, and may also perform or seek to perform investment banking or advisory services for or relating to these companies and may also be represented in the supervisory board or any other committee of these companies.

For the purpose of calculating whether BOBCAPS and its affiliates hold, beneficially own, or control, including the right to vote for directors, one per cent or more of the equity shares of the subject company, the holdings of the issuer of the research report is also included.

BOBCAPS and its non-US affiliates may, to the extent permissible under applicable laws, have acted on or used this research to the extent that it relates to non-US issuers, prior to or immediately following its publication. Foreign currency denominated securities are subject to fluctuations in exchange rates that could have an adverse effect on the value or price of or income derived from the investment. In addition, investors in securities such as ADRs, the value of which are influenced by foreign currencies, effectively assume currency risk. In addition, options involve risks and are not suitable for all investors. Please ensure that you have read and understood the Risk disclosure document before entering into any derivative transactions.

No part of this material may be (1) copied, photocopied, or duplicated in any form by any means or (2) redistributed without BOBCAPS's prior written consent.

Company-specific disclosures under SEBI (Research Analysts) Regulations, 2014

The research analyst(s) or his/her relatives do not have any material conflict of interest at the time of publication of this research report.

BOBCAPS or its research analyst(s) or his/her relatives do not have any financial interest in the subject company. BOBCAPS or its research analyst(s) or his/her relatives do not have actual/beneficial ownership of one per cent or more securities in the subject company at the end of the month immediately preceding the date of publication of this report.

The research analyst(s) has not received any compensation from the subject company or third party in the past 12 months in connection with research report/activities. Compensation of the research analyst(s) is not based on any specific merchant banking, investment banking or brokerage service transactions.

BOBCAPS or its research analyst(s) is not engaged in any market making activities for the subject company.

The research analyst(s) has not served as an officer, director or employee of the subject company.

BOBCAPS or its associates may have material conflict of interest at the time of publication of this research report.

BOBCAPS's associates may have financial interest in the subject company. BOBCAPS's associates may hold actual / beneficial ownership of one per cent or more securities in the subject company at the end of the month immediately preceding the date of publication of this report.

BOBCAPS or its associates may have managed or co-managed a public offering of securities for the subject company or may have been mandated by the subject company for any other assignment in the past 12 months.

BOBCAPS may have received compensation from the subject company in the past 12 months. BOBCAPS may from time to time solicit or perform investment banking services for the subject company. BOBCAPS or its associates may have received compensation from the subject company in the past 12 months for services in respect of managing or co-managing public offerings, corporate finance, investment banking or merchant banking, brokerage services or other advisory services in a merger or specific transaction. BOBCAPS or its associates may have received compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past 12 months.

Other disclaimers

BOBCAPS and MAYBANK (as defined below) make no representation or warranty, express or implied, as to the accuracy or completeness of any information obtained from third parties and expressly disclaim the merchantability, suitability, quality and fitness of this report. The information in this report has not been independently verified, is provided on an "as is" basis, should not be relied on by you in connection with any contract or commitment, and should not be used as a substitute for enquiries, procedures and advice which ought to be undertaken by you. This report also does not constitute an offer or solicitation to buy or sell any securities referred to herein and you should not construe this report as investment advice. All opinions and estimates contained in this report constitute BOBCAPS's judgment as of the date of this report and are subject to change without notice, and there is no obligation on BOBCAPS or MAYBANK to update this report upon issuance. This report and the information contained herein may not be reproduced, redistributed, disseminated or copied by any means without the prior consent of BOBCAPS and MAYBANK.

To the full extent permitted by law neither BOBCAPS, MAYBANK nor any of their respective affiliates, nor any other person, accepts any liability howsoever arising, whether in contract, tort, negligence, strict liability or any other basis, including without limitation, direct or indirect, special, incidental, consequential or punitive damages arising from any use of this report or the information contained herein. By accepting this report, you agree and undertake to fully indemnify and hold harmless BOBCAPS and MAYBANK from and against claims, charges, actions, proceedings, losses, liabilities, damages, expenses and demands (collectively, the "Losses") which BOBCAPS and/or MAYBANK may incur or suffer in any jurisdiction including but not limited to those Losses incurred by BOBCAPS and/or MAYBANK as a result of any proceedings or actions brought against them by any regulators and/or authorities, and which in any case are directly or indirectly occasioned by or result from or are attributable to anything done or omitted in relation to or arising from or in connection with this report.

Distribution into the United Kingdom ("UK"):

This research report will only be distributed in the United Kingdom, in accordance with the applicable laws and regulations of the UK, by Maybank Securities (London) Ltd) ("MSL") who is authorised and regulated by the Financial Conduct Authority ("FCA") in the United Kingdom (MSL and its affiliates are collectively referred to as "MAYBANK"). BOBCAPS is not authorized to directly distribute this research report in the UK.

This report has not been prepared by BOBCAPS in accordance with the UK's legal and regulatory requirements.

This research report is for distribution only to, and is solely directed at, selected persons on the basis that those persons: (a) are eligible counterparties and professional clients of MAYBANK as selected by MAYBANK solely at its discretion; (b) have professional experience in matters relating to investments falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended from time to time (the "Order"), or (c) fall within Article 49(2)(a) to (d) (high net worth companies, unincorporated associations, etc. as mentioned in the stated Article) of the Order; (all such persons together being referred to as "relevant persons").

This research report is directed only at relevant persons and must not be acted on or relied on by any persons who are not relevant persons. Any investment or investment activity to which this material relates is available only to relevant persons and will be engaged in only with relevant persons.

The relevant person as recipient of this research report is not permitted to reproduce, change, remove, pass on, distribute or disseminate the data or make it available to third parties without the written permission of BOBCAPS or MAYBANK. Any decision taken by the relevant person(s) pursuant to the research report shall be solely at their costs and consequences and BOBCAPS and MAYBANK shall not have any liability of whatsoever nature in this regard.

No distribution into the US:

This report will not be distributed in the US and no US person may rely on this communication.

Other jurisdictions

This report has been prepared in accordance with SEBI (Research Analysts) Regulations and not in accordance with local regulatory requirements of any other jurisdiction. In any other jurisdictions, this report is only for distribution (subject to applicable legal or regulatory restrictions) to professional, institutional or sophisticated investors as defined in the laws and regulations of such jurisdictions by Maybank Securities Pte Ltd. (Singapore) and / or by any broker-dealer affiliate or such other affiliate as determined by Malayan Banking Berhad.

If the recipient of this report is not as specified above, then it should not act upon this report and return the same to the sender.

By accepting this report, you agree to be bound by the foregoing limitations.